HOME >> BIOLOGY >> NEWS
Progress toward a more targeted treatment of Alzheimer's disease

Leuven, Belgium - Leuven Scientists from the Flanders Interuniversity Institute for Biotechnology (VIB) connected with the Catholic University of Leuven have shed a little more light on Alzheimer's disease. They've gone deeply into the operation of γ-secretase, a crucial factor in the origin of the disease. Their research has revealed that the action of γ-secretase is not homogeneous - as previously assumed - but quite differentiated. This discovery opens up perspectives for new medicines that will have fewer undesired side effects than current medicines do.

Alzheimer's disease
Alzheimer's disease, a degenerative disease that gradually and progressively destroys brain cells, affects between 50% and 70% of all cases of dementia and is therefore the major form of dementia. About 100,000 people suffer from this disease in Belgium. The damage caused to memory and mental functioning makes it one of today's most frightening syndromes. In particular, the first realization of the loss of any sense of reality is extremely difficult to accept. So, science continues to search feverishly for ways to treat the disease.

The role of γ-secretase
Alzheimer's disease involves a kind of plaque that forms in the brain cells. Several years ago, Bart De Strooper and other researchers deciphered the process by which the plaques originate. A major role in this process is played by γ-secretase, an enzyme that cuts proteins in a particular place. Sometimes the γ-secretase cleavage goes wrong, causing the creation of a by-product that sticks together and precipitates - thus forming the plaque. In their quest for new medicines, scientists are investigating this key role of ?-secretase to try to find substances that are able to block the formation of plaques. A thorough understanding of γ-secretase is therefore critical.

Diverse tissue-specific activity
γ-secretase is divided into several entitie
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Feb-2005


Page: 1 2

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress toward a targeted therapy for a specific form of leukemia
3. Progress against sarcoma
4. Progress toward artificial photosynthesis?
5. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
6. Progress in battle against life-threatening acute allergy
7. Progress report on Homogeneous Assay project
8. Progress being made in exploring potential use of stem cells to treat heart disease
9. Media Invite: Dinner to award prize for Progress in Cancer Research
10. Progress needed on global regime for access to genetic resources and benefit-sharing
11. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Progress toward more targeted treatment Alzheimer disease

(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... announced that longer-term toxicology studies for its newly ... arthritis, or RA, have been completed. The results ... the U.S. Food and Drug Administration. The feedback ... completion of the ongoing first-in-human study. Additional preclinical ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
Cached News: